Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study

被引：22
作者：
Accurso, Vincenzo [1 ]
Santoro, Marco [2 ]
Raso, Simona [2 ]
Contrino, Angelo Davide [1 ]
Casimiro, Paolo [1 ]
Di Piazza, Florinda [2 ]
Perez, Alessandro [2 ]
Russo, Antonio [2 ]
Siragusa, Sergio [1 ]
机构：
[1] Univ Hosp Policlin Paolo Giaccone, Div Hematol, Via Vespro 129, I-90127 Palermo, Italy
[2] Univ Palermo, Dept Surg Oncol & Stomatol Disciplines, Palermo, Italy
来源：
HEMATOLOGY REPORTS | 2019年 / 11卷 / 04期
关键词：
Splenomegaly; Polycythemia Vera; essential thrombocythemia; INTERNATIONAL WORKING GROUP; PRIMARY MYELOFIBROSIS; AVAILABLE THERAPY; PREDICT SURVIVAL; RUXOLITINIB; THROMBOSIS; NEOPLASMS; SCORE; CLASSIFICATION; VALIDATION;
D O I：
10.4081/hr.2019.8281
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with these diseases. We aimed to study the impact that such alteration has on thrombotic risk and on the survival of patients with essential thrombocythemia and patients with Polycythemia Vera (PV). We studied the relationship between splenomegaly (and its grade), thrombosis and survival in 238 patients with et and 165 patients with PV followed at our center between January 1997 and May 2019.
引用
收藏
页码：95 / 97
页数：3
相关论文
共 20 条
  • [1] Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients
    Andriani, Alessandro
    Latagliata, Roberto
    Anaclerico, Barbara
    Spadea, Antonio
    Rago, Angela
    Di Veroli, Ambra
    Spirito, Francesca
    Porrini, Raffaele
    De Muro, Marianna
    Leonetti, Sabrina Crescenzi
    Villiva, Nicoletta
    De Gregoris, Cinzia
    Montefusco, Enrico
    Polverelli, Nicola
    Santoro, Cristina
    Breccia, Massimo
    Cimino, Giuseppe
    Majolino, Ignazio
    Mazzucconi, Maria Gabriella
    Vianelli, Nicola
    Alimena, Giuliana
    Montanaro, Marco
    Palandri, Francesca
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) : 318 - 321
  • [2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [3] The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
    Barbui, Tiziano
    Thiele, Jurgen
    Gisslinger, Heinz
    Kvasnicka, Hans Michael
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Orazi, Attilio
    Tefferi, Ayalew
    [J]. BLOOD CANCER JOURNAL, 2018, 8 : 15
  • [4] Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
    Barbui, Tiziano
    Finazzi, Guido
    Carobbio, Alessandra
    Thiele, Juergen
    Passamonti, Francesco
    Rumi, Elisa
    Ruggeri, Marco
    Rodeghiero, Francesco
    Randi, Maria Luigia
    Bertozzi, Irene
    Gisslinger, Heinz
    Buxhofer-Ausch, Veronika
    De Stefano, Valerio
    Betti, Silvia
    Rambaldi, Alessandro
    Vannucchi, Alessandro M.
    Tefferi, Ayalew
    [J]. BLOOD, 2012, 120 (26) : 5128 - 5133
  • [5] Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
    Barbui, Tiziano
    Barosi, Giovanni
    Birgegard, Gunnar
    Cervantes, Francisco
    Finazzi, Guido
    Griesshammer, Martin
    Harrison, Claire
    Hasselbalch, Hans Carl
    Hehlmann, Rudiger
    Hoffman, Ronald
    Kiladjian, Jean-Jacques
    Kroeger, Nicolaus
    Mesa, Ruben
    McMullin, Mary F.
    Pardanani, Animesh
    Passamonti, Francesco
    Vannucchi, Alessandro M.
    Reiter, Andreas
    Silver, Richard T.
    Verstovsek, Srdan
    Tefferi, Ayalew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) : 761 - 770
  • [6] Prognosis of Primary Myelofibrosis in the Genomic Era
    Bose, Prithviraj
    Verstovsek, Srdan
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S105 - S113
  • [7] Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
    Bryan, Jeffrey C.
    Verstovsek, Srdan
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1125 - 1142
  • [8] Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
    Cerquozzi, S.
    Barraco, D.
    Lasho, T.
    Finke, C.
    Hanson, C. A.
    Ketterling, R. P.
    Pardanani, A.
    Gangat, N.
    Tefferi, A.
    [J]. BLOOD CANCER JOURNAL, 2017, 7
  • [9] Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
    Cervantes, Francisco
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa Kathrin
    Sirulnik, Andres
    Stalbovskaya, Viktoriya
    McQuitty, Mari
    Hunter, Deborah S.
    Levy, Richard S.
    Passamonti, Francesco
    Barbui, Tiziano
    Barosi, Giovanni
    Harrison, Claire N.
    Knoops, Laurent
    Gisslinger, Heinz
    [J]. BLOOD, 2013, 122 (25) : 4047 - 4053
  • [10] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Cervantes, Francisco
    Dupriez, Brigitte
    Pereira, Arturo
    Passamonti, Francesco
    Reilly, John T.
    Morra, Enrica
    Vannucchi, Alessandro M.
    Mesa, Ruben A.
    Demory, Jean-Loup
    Barosi, Giovanni
    Rumi, Elisa
    Tefferi, Ayalew
    [J]. BLOOD, 2009, 113 (13) : 2895 - 2901
12